Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL
Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL
SABCS 2023: Latest breast cancer diagnostics guidelines
Cancer care in Needle Hospital, Hargeisa, Somaliland
Relapsed refractory multiple myeloma
The evolving paradigm in management of Multiple Myeloma
First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer
Trial investigates multiparametric prognostic score in early HR+/HER2- breast cancer
ESMO 2023: Highlights and analysis
Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Lung Cancer
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab